These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39132033)

  • 1. Vasoconstrictor Therapy for Acute Kidney Injury Hepatorenal Syndrome: A Meta-Analysis of Randomized Studies.
    Singal AK; Palmer G; Melick L; Abdallah M; Kwo P
    Gastro Hep Adv; 2023; 2(4):455-464. PubMed ID: 39132033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
    Flamm SL; Wong F; Ahn J; Kamath PS
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population.
    Reddy KR; Weinberg EM; Gonzalez SA; Izzy MJ; Simonetto DA; Frederick RT; Rubin RA; Fricker Z; Ikahihifo-Bender J; Harte M; Garcia S; Campbell K; Olofson A; Razavi RF; James JM; Patel H; Kim-Lee G; Witkiewicz S; Tobin W; Jamil K
    Liver Transpl; 2024 Oct; 30(10):1026-1038. PubMed ID: 38771635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
    J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
    Gonzalez SA; Chirikov VV; Wang WJ; Huang X; Jamil K; Simonetto DA
    Clin Transl Gastroenterol; 2023 Dec; 14(12):e00627. PubMed ID: 37622521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
    Kulkarni AV; Lee J; Reddy KR
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
    Erstad BL
    Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
    Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
    Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
    Nanda A; Reddy R; Safraz H; Salameh H; Singal AK
    J Clin Gastroenterol; 2018 Apr; 52(4):360-367. PubMed ID: 28991106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
    Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
    Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
    Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Terlipressin Infusion in Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI): A Retrospective Observational Study.
    Gowda M; Dilipbhai DM; Jalihal U; Kumar MP; Gowda S B; Jain A; Ganjoo N
    Cureus; 2024 Aug; 16(8):e66581. PubMed ID: 39252705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
    Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies.
    Curry MP; Vargas HE; Befeler AS; Pyrsopoulos NT; Patwardhan VR; Jamil K
    Hepatol Commun; 2023 Jan; 7(1):e1307. PubMed ID: 36633470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
    Arora V; Maiwall R; Rajan V; Jindal A; Muralikrishna Shasthry S; Kumar G; Jain P; Sarin SK
    Hepatology; 2020 Feb; 71(2):600-610. PubMed ID: 30076614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
    Weinberg EM; Wong F; Vargas HE; Curry MP; Jamil K; Pappas SC; Sharma P; Reddy KR
    Liver Transpl; 2024 Apr; 30(4):347-355. PubMed ID: 37801553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.
    Sridharan K; Sivaramakrishnan G
    J Gen Intern Med; 2018 Jan; 33(1):97-102. PubMed ID: 28924736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion.
    Weinberg E; Rahematpura S; Gonzalez SA; Izzy MJ; Simonetto DA; Frederick RT; Rubin RA; Ikahihifo-Bender J; Harte M; Kim-Lee G; Witkiewicz S; Tobin W; Jamil K; Fricker Z; Reddy KR
    Contemp Clin Trials Commun; 2023 Dec; 36():101211. PubMed ID: 37953795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.